Ginkgo Bioworks reported operational challenges, including decreased R&D and G&A expenses and difficulties securing international contracts.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ginkgo Bioworks reported operational challenges, including decreased R&D and G&A expenses and difficulties securing international contracts.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ginkgo Bioworks
American biotechnology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GuruFocus.comGinkgo Bioworks Holdings Inc (DNA) Q2 2025 Earnings Call Highlights: Strategic Cost Management ... Cell Engineering Revenue: $39 million in Q2 2025, up 8% year-over-year. Biosecurity Revenue: $10 mil